即穿型Flixene^(TM)人工血管动静脉瘘的临床应用结果  

Clinical application outcomes of Flixene^(TM)arteriovenous graft

作　　者：吴厂 米兰化 施娅雪[1] 鲍雪东 刘思洁[1] 符欣漪 Wu Chang;Mi Lanhua;Shi Yaxue;Bao Xuedong;Liu Sijie;Fu Xinyi(Department of Vascular Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院血管外科,上海200032

出　　处：《中国血管外科杂志(电子版)》2025年第1期61-64,69,共5页Chinese Journal of Vascular Surgery(Electronic Version)

摘　　要：目的总结Flixene^(TM)即穿型人工血管动静脉内瘘临床应用的结果。方法回顾性分析2019年8月至2023年12月上海中医药大学附属龙华医院血管外科接受Flixene^(TM)即穿型人工血管建立血液透析通路的111例患者临床资料,总结通路血管情况、手术结果和随访期间通畅率和并发症发生率。结果临床技术成功率100%,无围手术期并发症发生。术后首次穿刺时间为15~504 h,其中101例(91.0%)术后24 h内即首次穿刺透析。5例患者失访,随访率95.5%,平均随访时间(661.02±399.85)d。随访期间9例患者因为其他原因死亡;22例患者出现血栓、41例出现狭窄、8例发生穿刺点感染。穿刺部位未出现皮下血肿、血清肿、假性动脉瘤及窃血综合征等并发症。患者术后1、2、3年的一期通畅率分别为56.3%、27.9%、17.6%;术后1、2、3、4年的一期辅助通畅率和二期通畅率分别为86.6%、72.2%、61.7%、61.7%和97.7%、94.5%、91.2%、91.2%。结论Flixene^(TM)即穿型人工血管早期穿刺安全可行,且能满足患者较长时间血液透析的临床应用要求。Objective To summarize the clinical outcomes of Flixene^(TM)arteriovenous graft.Methods The clinical data of 111 patients who received Flixene^(TM)arteriovenous graft to establish hemodialysis access in the Department of Vascular Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine from August 2019 to December 2023 were analyzed retrospectively.The hemodialysis access conditions,surgical results,patency rate and complication rate during follow-up were summarized.Results The clinical technical success rate was 100%,and no perioperative complications occurred.The time to first cannulation after surgery was 15-504 h,of which 101 patients(91.0%)cannulated within 24 h after surgery.Five patients were lost to follow-up,with a follow-up rate of 95.5%and an average follow-up time of 661.02±399.85 days.During the follow-up period,9 patients died due to other causes.22 patients developed thrombosis,41 patients developed stenosis,and 8 patients developed cannulation site infection.No complications such as subcutaneous haematomas,seromas,pseudoaneurysms or steal blood syndrome occurred at the cannulation sites.The primary patency rates of patients at 1,2 and 3 years after surgery were 56.3%,27.9%and 17.6%,respectively.The primary assisted patency rates and secondary patency rates at 1,2,3 and 4 years after surgery were 86.6%,72.2%,61.7%,61.7%and 97.7%,94.5%,91.2%and 91.2%,respectively.Conclusion Early cannulation of Flixene^(TM)arteriovenous graft is safe and feasible,and it can fulfill the clinical application requirements of patients with long-term hemodialysis.

关 键 词：血液透析 动静脉内瘘 人工血管 血管通路 通畅率 

分 类 号：R459.5[医药卫生—治疗学]